Literature DB >> 32294158

Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia.

Mrinal M Patnaik1, David A Sallman2, Abhishek A Mangaonkar1, Rachel Heuer1, Jeffery Hirvela1, Darci Zblewski1, Aref Al-Kali1, Moritz Binder1, Maria E Balasis2, Hannah Newman2, Christopher Letson2, Traci L Kruer2, Naseema Gangat1, Rami S Komrokji2, Ayalew Tefferi1, Adrian Lo3, Ted Shih4, Cameron Durrant3, Alan F List2, Eric Padron2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32294158      PMCID： PMC7531999          DOI： 10.1182/blood.2019004352

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  11 in total

1.  Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients.

Authors:  Tucker Coston; Prateek Pophali; Rangit Vallapureddy; Terra L Lasho; Christy M Finke; Rhett P Ketterling; Ryan Carr; Moritz Binder; Abhishek A Mangaonkar; Naseema Gangat; Aref Al-Kali; Mark Litzow; Darci Zblewski; Animesh Pardanani; Ayalew Tefferi; Mrinal M Patnaik
Journal:  Am J Hematol       Date:  2019-05-03       Impact factor: 10.047

2.  An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.

Authors:  Michael R Savona; Luca Malcovati; Rami Komrokji; Ramon V Tiu; Tariq I Mughal; Attilio Orazi; Jean-Jacques Kiladjian; Eric Padron; Eric Solary; Raoul Tibes; Raphael Itzykson; Mario Cazzola; Ruben Mesa; Jaroslaw Maciejewski; Pierre Fenaux; Guillermo Garcia-Manero; Aaron Gerds; Guillermo Sanz; Charlotte M Niemeyer; Francisco Cervantes; Ulrich Germing; Nicholas C P Cross; Alan F List
Journal:  Blood       Date:  2015-01-26       Impact factor: 22.113

Review 3.  Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management.

Authors:  Mrinal M Patnaik; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2018-06       Impact factor: 10.047

4.  Granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced STAT5 activation and target-gene expression during human monocyte/macrophage differentiation.

Authors:  Anne Lehtonen; Sampsa Matikainen; Minja Miettinen; Ilkka Julkunen
Journal:  J Leukoc Biol       Date:  2002-03       Impact factor: 4.962

Review 5.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

6.  ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.

Authors:  M M Patnaik; R Itzykson; T L Lasho; O Kosmider; C M Finke; C A Hanson; R A Knudson; R P Ketterling; A Tefferi; E Solary
Journal:  Leukemia       Date:  2014-04-03       Impact factor: 11.528

7.  Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.

Authors:  Jane Merlevede; Nathalie Droin; Tingting Qin; Kristen Meldi; Kenichi Yoshida; Margot Morabito; Emilie Chautard; Didier Auboeuf; Pierre Fenaux; Thorsten Braun; Raphael Itzykson; Stéphane de Botton; Bruno Quesnel; Thérèse Commes; Eric Jourdan; William Vainchenker; Olivier Bernard; Noemie Pata-Merci; Stéphanie Solier; Velimir Gayevskiy; Marcel E Dinger; Mark J Cowley; Dorothée Selimoglu-Buet; Vincent Meyer; François Artiguenave; Jean-François Deleuze; Claude Preudhomme; Michael R Stratton; Ludmil B Alexandrov; Eric Padron; Seishi Ogawa; Serge Koscielny; Maria Figueroa; Eric Solary
Journal:  Nat Commun       Date:  2016-02-24       Impact factor: 14.919

8.  GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia.

Authors:  Eric Padron; Jeffrey S Painter; Sateesh Kunigal; Adam W Mailloux; Kathy McGraw; Jessica M McDaniel; Eunhee Kim; Christopher Bebbington; Mark Baer; Geoffrey Yarranton; Jeffrey Lancet; Rami S Komrokji; Omar Abdel-Wahab; Alan F List; Pearlie K Epling-Burnette
Journal:  Blood       Date:  2013-04-30       Impact factor: 25.476

9.  The genomic landscape of juvenile myelomonocytic leukemia.

Authors:  Elliot Stieglitz; Amaro N Taylor-Weiner; Tiffany Y Chang; Laura C Gelston; Yong-Dong Wang; Tali Mazor; Emilio Esquivel; Ariel Yu; Sara Seepo; Scott Olsen; Mara Rosenberg; Sophie L Archambeault; Ghada Abusin; Kyle Beckman; Patrick A Brown; Michael Briones; Benjamin Carcamo; Todd Cooper; Gary V Dahl; Peter D Emanuel; Mark N Fluchel; Rakesh K Goyal; Robert J Hayashi; Johann Hitzler; Christopher Hugge; Y Lucy Liu; Yoav H Messinger; Donald H Mahoney; Philip Monteleone; Eneida R Nemecek; Philip A Roehrs; Reuven J Schore; Kimo C Stine; Clifford M Takemoto; Jeffrey A Toretsky; Joseph F Costello; Adam B Olshen; Chip Stewart; Yongjin Li; Jing Ma; Robert B Gerbing; Todd A Alonzo; Gad Getz; Tanja Gruber; Todd Golub; Kimberly Stegmaier; Mignon L Loh
Journal:  Nat Genet       Date:  2015-10-12       Impact factor: 38.330

10.  Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma.

Authors:  Nestor A Molfino; Piotr Kuna; Jonathan A Leff; Chad K Oh; Dave Singh; Marlene Chernow; Brian Sutton; Geoffrey Yarranton
Journal:  BMJ Open       Date:  2016-01-06       Impact factor: 2.692
View more
  15 in total

Review 1.  Treatment advances for pediatric and adult onset neoplasms with monocytosis.

Authors:  Kristen B McCullough; Alexis K Kuhn; Mrinal M Patnaik
Journal:  Curr Hematol Malig Rep       Date:  2021-03-16       Impact factor: 3.952

Review 2.  Chronic myelomonocytic leukemia diagnosis and management.

Authors:  Onyee Chan; Aline Renneville; Eric Padron
Journal:  Leukemia       Date:  2021-03-13       Impact factor: 11.528

Review 3.  Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia.

Authors:  Aline Renneville; Mrinal M Patnaik; Onyee Chan; Eric Padron; Eric Solary
Journal:  Leukemia       Date:  2021-06-26       Impact factor: 11.528

4.  RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis.

Authors:  Ryan M Carr; Denis Vorobyev; Terra Lasho; David L Marks; Ezequiel J Tolosa; Alexis Vedder; Luciana L Almada; Andrey Yurcheko; Ismael Padioleau; Bonnie Alver; Giacomo Coltro; Moritz Binder; Stephanie L Safgren; Isaac Horn; Xiaona You; Eric Solary; Maria E Balasis; Kurt Berger; James Hiebert; Thomas Witzig; Ajinkya Buradkar; Temeida Graf; Peter Valent; Abhishek A Mangaonkar; Keith D Robertson; Matthew T Howard; Scott H Kaufmann; Christopher Pin; Martin E Fernandez-Zapico; Klaus Geissler; Nathalie Droin; Eric Padron; Jing Zhang; Sergey Nikolaev; Mrinal M Patnaik
Journal:  Nat Commun       Date:  2021-05-18       Impact factor: 14.919

5.  Mutated GM-CSF-based CAR-T cells targeting CD116/CD131 complexes exhibit enhanced anti-tumor effects against acute myeloid leukaemia.

Authors:  Aiko Hasegawa; Shoji Saito; Shogo Narimatsu; Shigeru Nakano; Mika Nagai; Hideki Ohnota; Yoichi Inada; Hirokazu Morokawa; Ikumi Nakashima; Daisuke Morita; Yuichiro Ide; Kazuyuki Matsuda; Haruko Tashiro; Shigeki Yagyu; Miyuki Tanaka; Yozo Nakazawa
Journal:  Clin Transl Immunology       Date:  2021-05-06

6.  How I diagnose and treat chronic myelomonocytic leukemia.

Authors:  Mrinal M Patnaik
Journal:  Haematologica       Date:  2022-07-01       Impact factor: 11.047

7.  Special considerations in the management of patients with myelodysplastic myndrome / myeloproliferative neoplasm overlap syndromes during the SARS-CoV-2 pandemic.

Authors:  Mrinal M Patnaik; Terra Lasho; Eric Padron; Kristen McCullough; Aref Al-Kali; Ayalew Tefferi; Amer M Zeidan; Naseema Gangat; Michael Savona; David P Steensma; Eric Solary
Journal:  Am J Hematol       Date:  2020-05-22       Impact factor: 10.047

8.  Autocrine GMCSF Signaling Contributes to Growth of HER2+ Breast Leptomeningeal Carcinomatosis.

Authors:  Khairul I Ansari; Arunoday Bhan; Mika Saotome; Antariksh Tyagi; Bony De Kumar; Clara Chen; Motoki Takaku; Rahul Jandial
Journal:  Cancer Res       Date:  2021-07-09       Impact factor: 12.701

9.  Cytokine-like protein 1-induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML.

Authors:  Margaux Sevin; Franck Debeurme; Lucie Laplane; Séverine Badel; Margot Morabito; Hanna L Newman; Miguel Torres-Martin; Qin Yang; Bouchra Badaoui; Orianne Wagner-Ballon; Véronique Saada; Dorothée Sélimoglu-Buet; Laurence Kraus-Berthier; Sébastien Banquet; Alix Derreal; Pierre Fenaux; Raphael Itzykson; Thorsten Braun; Gabriel Etienne; Celine Berthon; Sylvain Thépot; Oliver Kepp; Guido Kroemer; Eric Padron; Maria E Figueroa; Nathalie Droin; Eric Solary
Journal:  Blood       Date:  2021-06-17       Impact factor: 22.113

10.  Chronic myelomonocytic leukaemia stem cell transcriptomes anticipate disease morphology and outcome.

Authors:  Daniel H Wiseman; Syed M Baker; Arundhati V Dongre; Kristian Gurashi; Joanna A Storer; Tim Cp Somervaille; Kiran Batta
Journal:  EBioMedicine       Date:  2020-08-04       Impact factor: 8.143
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.